Enhance Diagnostics, a clinical-stage company focused on non-invasive diagnostic solutions announced today a key leadership transition. Dr. Matthew Leming, PhD, formerly Chief Scientific Officer, has been appointed Chief Executive Officer. Dr. Calvin Goforth, who previously served as CEO, will transition to the role of Executive Chairman.
Dr. Leming brings a strong track record in scientific research, healthcare innovation, and medtech commercialization. With a PhD in Biology from the University of Notre Dame and postdoctoral training at the University of Pittsburgh Medical Center, he has more than a decade of experience in scientific research and seven years in healthcare startup management and technology transfer. His background spans medical devices, mobile health platforms, drug discovery, and academic-to-commercial translation.
“I am honored to step into the role of CEO at such a pivotal time for Enhance Diagnostics. The Breakthrough Device designation for Breeze™ validates the hard work of our team and highlights the transformative potential of our platform. I look forward to leading the company as we advance toward delivering life-changing diagnostic solutions for patients with metabolic disorders, chronic kidney disease, and beyond” said Dr. Leming.
Enhance Diagnostics recently received FDA Breakthrough Device designation for its flagship product, Breeze™, a novel breath-based diagnostic platform designed for patients diagnosed with a urea cycle disorder (UCD). This recognition underscores the company’s potential to transform the way rare metabolic conditions are detected and monitored.
In addition to his role at Enhance Diagnostics, Dr. Leming serves as an Entrepreneur in Residence at VIC Tech, supporting early-stage life science ventures nationwide.
Dr. Goforth, who led Enhance Diagnostics through its early growth and development, will remain closely involved in shaping the company’s long-term vision and strategy as Chairman of the Board.
“I am proud of the progress Enhance Diagnostics has made under our talented team, and I’m confident that Matt’s scientific expertise and leadership will guide the company through its next stage of growth. As Executive Chairman, I will continue to support the company’s long-term vision and strategy and help ensure that our platform reaches its full potential for improving patient care” states Dr. Goforth.
About VIC Tech
Enhance Diagnostics is part of the portfolio of VIC Tech, a venture studio focused on creating companies from innovative academic research. Breeze is the third device from a VIC Tech portfolio company to receive Breakthrough Device Designation from the FDA, highlighting VIC’s consistent track record of advancing impactful health technologies toward clinical and commercial success.